Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 5Breast 4Thoracic 3Sarcoma 3Lymphoid 3Genitourinary 3Tumor-Agnostic 2Myeloid 2Gynecologic 2CNS 2Other solid neoplasm 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
LY3023414 × Tumor-Agnostic × Clear all
NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Eli Lilly and Company

Available
Tumor-Agnostic

Neoplasms

NCT02536586 2018-07-24

A Study of LY3023414 in Japanese Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡